Mirum Pharmaceuticals (MIRM) Operating Leases (2019 - 2026)

Mirum Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 59.57% year-over-year to $11.2 million in Q1 2026; TTM through Mar 2026 was $11.2 million, a 59.57% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, down 5.72% from the prior year.
• Operating Leases rose to $11.2 million in Q1 2026 per MIRM's latest filing, from $7.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $11.2 million in Q1 2026 and bottomed at $617000.0 in Q4 2023.
• The 5-year median for Operating Leases is $1.7 million (2022), against an average of $4.8 million.
• Across the five-year window, Operating Leases sank 50.91% in 2023 and soared 1192.06% in 2024, its largest moves.
• Year by year, Operating Leases stood at $1.3 million in 2022, then sank by 50.91% to $617000.0 in 2023, then surged by 1192.06% to $8.0 million in 2024, then fell by 5.72% to $7.5 million in 2025, then surged by 48.68% to $11.2 million in 2026.
• Per Business Quant, the three latest MIRM Operating Leases figures stand at $11.2 million (Q1 2026), $7.5 million (Q4 2025), and $9.4 million (Q3 2025).